Importantly, increased mTORC1 activity and Mcl-1 level represented a pro-survival cellular response to the mild to moderate stress triggered by these sunitinib doses since inhibiting mTORC1 or depleting Mcl-1 sensitized cancer cells to tolerated doses (Elgendy et al., 2016). This evidence concerns the gene MCL1 and cancer.